Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

T9191

Sigma-Aldrich

Anti-TRAIL antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

Synonym(s):

Anti-Apo-2L

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD01868284
UNSPSC Code:
12352203

biological source

rabbit

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 35 kDa

species reactivity

human

technique(s)

microarray: suitable
western blot: 1 μg/mL using human HeLa cell extract

UniProt accession no.

P50591

shipped in

wet ice

storage temp.

2-8°C

Gene Information

human ... TNFSF10(8743)

Immunogen

synthetic peptide corresponding to amino acids 261-277 of the C-terminal region of human TRAIL (TNF-Related Apoptosis-Inducing Ligand).

Physical form

Supplied as 1.0 mg/ml of IgG fraction of antiserum in phosphate buffered saline containing 0.02% sodium azide

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hanjie Yi et al.
Oncology letters, 16(4), 4768-4772 (2018-09-15)
Non-small cell lung cancer (NSCLC) presents severe threats to the lives of patients. Gefitinib is one of the first-line drugs available for the treatment of NSCLC in the clinical setting. The present study investigated the effects of gefitinib on NSCLC
Ufuk Mert et al.
Cancers, 11(8) (2019-08-17)
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding clinical trials were disappointing. Meanwhile, it emerged that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service